Explore a selection of our essential drug information below, or:
Identification
- Summary
Vaborbactam is a beta lactamase inhibitor used to treat complicated urinary tract infections.
- Brand Names
- Vabomere
- Generic Name
- Vaborbactam
- DrugBank Accession Number
- DB12107
- Background
Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.2 It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of vaborbactam and Meropenem for intravenous administration. Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target.Label The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Vaborbactam (DB12107)
- Weight
- Average: 297.13
Monoisotopic: 297.084224 - Chemical Formula
- C12H16BNO5S
- Synonyms
- Vaborbactam
- External IDs
- RPX-7009
- RPX7009
Pharmacology
- Indication
Indicated in combination with meropenem for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.Label
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Complicated urinary tract infection caused by enterobacter cloacae Combination Product in combination with: Meropenem (DB00760) •••••••••••• Used in combination to treat Complicated urinary tract infection caused by escherichia coli Combination Product in combination with: Meropenem (DB00760) •••••••••••• Used in combination to treat Complicated urinary tract infection caused by klebsiella pneumoniae Combination Product in combination with: Meropenem (DB00760) •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Vaborbactam shows no antibacterial activity alone; it serves to restore the antibacterial activity of other antibacterial agents such as meropenem by attenuating their degradation by inhibiting certain serine beta-lactamases of microorganisms.Label Vaborbactam does not decrease the activity of meropenem against meropenem-susceptible organisms.Label Vaborbactam in combination with meropenem, which is a penem antibacterial drug, potentiates the bactericidal actions of meropenem against carbapenem-resistant KPC-containing Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae in a concentration-dependent manner.3 It restored the antimicrobial activity of meropenem in animal models of infection caused by some meropenem non-susceptible KPC-producing Enterobacteriaceae.Label
- Mechanism of action
Vaborbactam is a cyclic boronic acid pharmacophore β-lactamase inhibitor that elicits potent inhibition of Klebsiella pneumoniae carbapenemase (KPC) enzymes and other Ambler class A and C enzymes such as serine β-lactamases that confer resistance to commonly-used antibiotics such as Carbapenems.1 Vaborbactam is a potent inhibitor of class A carbapenemases, such as KPC, as well as an inhibitor of other class A (CTX-M, SHV, TEM) and class C (P99, MIR, FOX) beta-lactamases.2 Vaborbactam interacts with β-lactamases of Ambler classes A and C via precovalent and covalent binding.1 It exerts no inhibitory actions on class D or class B carbapenemases.2 The production of contemporary β-lactamase by bacterial isolates potentiate the degradation of β-lactam antibiotic agents, rendering them clinically ineffective and posing challenges for patients receiving the standard antibiotic therapy. In combination with meropenem, varborbactam acts as a non-suicidal beta-lactamase inhibitor that protects meropenem from degradation mediated by serine beta-lactamases such as Klebsiella pneumoniae carbapenemase (KPC).3
Target Actions Organism ABeta-lactamase inhibitorEnterobacter cloacae ABeta-lactamase inhibitorStaphylococcus aureus ACarbapenem-hydrolyzing beta-lactamase KPC inhibitorKlebsiella pneumoniae ABeta-lactamase inhibitorKlebsiella pneumoniae ABeta-lactamase CTX-M inhibitorEscherichia coli ABeta-lactamase inhibitorEscherichia coli ABeta-lactamase SHV-1 inhibitorKlebsiella pneumoniae ABeta-lactamase TEM inhibitorEscherichia coli ABeta-lactamase inhibitorKlebsiella pneumoniae ABeta-lactamase inhibitorKlebsiella pneumoniae - Absorption
The peak plasma concentrations (Cmax) and AUC of vaborbactam increase in a dose-proportional manner. In healthy adult subjects, the Cmax following administration of multiple 2 g dose as a 3-hour infusion was 55.6 mg/L and AUC was 588 mg•h/L. In patients with the same dosing regimen, the Cmax was 71.3 mg/L and AUC was 835 mg•h/L at steady state.Label The exposure of vaborbactam in terms of Cmax and AUC are not expected to change with repeated dosing, and there was no evidence of accumulation of vaborbactam in plasma in a repeated dosing study.3
- Volume of distribution
The steady-state volume of distribution of vaborbactam in patients was 18.6 L.Label
- Protein binding
The average serum protein binding of vaborbactam is approximately 33%.3
- Metabolism
Vaborbactam does not undergo metabolism.Label
- Route of elimination
Vaborbactam predominantly undergoes renal excretion, where about 75 to 95% of the dose is excreted unchanged in the urine over a 24 to 48 hour period.Label
- Half-life
The half life of vaborbactam in healthy subjects following multiple 2 g dose administration as a 3-hour infusion was 1.68 hours. The half life of vaborbactam following administration of 2 g by 3 hour infusion was 2.25 hours.Label
- Clearance
The mean renal clearance for vaborbactam was 8.9 L/h. The mean non-renal clearance for vaborbactam was 2.0 L/h indicating nearly complete elimination of vaborbactam by the renal route.Label The clearance of vaborbactam in healthy subjects following administration of multiple doses of 2 g as a 3-hour infusion was 10.9 L/h. The clearance of vaborbactam in patients following administration of 2 g by 3 hour infusion was 7.95 L/h.Label
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
In case of overdose, general supportive treatments should be initiated and hemodialysis to remove varobactam may be performed.Label In a pharmacokinetic study, mild lethargy observed in the highest-dose group.3
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Vaborbactam which could result in a lower serum level and potentially a reduction in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Vabomere Vaborbactam (1 g/2g) + Meropenem trihydrate (1 g/2g) Injection, powder, for solution Intravenous The Medicines Company 2017-10-02 2019-07-31 US 
Vabomere Vaborbactam (1 g/2g) + Meropenem trihydrate (1 g/2g) Injection, powder, for solution Intravenous Melinta Therapeutics, LLC 2017-10-02 Not applicable US Vaborem Vaborbactam (1 g) + Meropenem trihydrate (1 g) Injection, powder, for solution Intravenous Menarini International Operations Luxembourg S.A. 2020-12-16 Not applicable EU 
VABOREM Vaborbactam (1 G) + Meropenem (1 G) Injection, powder, for solution Intravenous Menarini International Operations Luxembourg S.A. 2019-06-08 Not applicable Italy 
Categories
- ATC Codes
- J01DH52 — Meropenem and vaborbactam
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as oxaborine derivatives. These are compounds containing a six-member aliphatic heterocycle made up of one oxygen atom, a boron atom, and three carbon atoms.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Metalloheterocyclic compounds
- Sub Class
- Oxaborine derivatives
- Direct Parent
- Oxaborine derivatives
- Alternative Parents
- Thiophenes / Heteroaromatic compounds / Boronic acid esters / Secondary carboxylic acid amides / Oxacyclic compounds / Organic metalloid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organonitrogen compounds / Organic oxides show 3 more
- Substituents
- 1,2-oxaborine derivative / Alkylborane / Aromatic heteromonocyclic compound / Boronic acid derivative / Boronic acid ester / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid derivative / Heteroaromatic compound show 13 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Escherichia coli
- Enterobacter cloacae
- Klebsiella pneumoniae
Chemical Identifiers
- UNII
- 1C75676F8V
- CAS number
- 1360457-46-0
- InChI Key
- IOOWNWLVCOUUEX-WPRPVWTQSA-N
- InChI
- InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1
- IUPAC Name
- 2-[(3R,6S)-2-hydroxy-3-[2-(thiophen-2-yl)acetamido]-1,2-oxaborinan-6-yl]acetic acid
- SMILES
- OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1
References
- General References
- Castanheira M, Rhomberg PR, Flamm RK, Jones RN: Effect of the beta-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5454-8. doi: 10.1128/AAC.00711-16. Print 2016 Sep. [Article]
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN: Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the beta-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6326-32. doi: 10.1128/AAC.00568-16. Print 2016 Oct. [Article]
- External Links
- PubChem Compound
- 56649692
- PubChem Substance
- 347828408
- ChemSpider
- 35035409
- BindingDB
- 50089084
- 1945213
- ChEMBL
- CHEMBL3317857
- PDBe Ligand
- 4D6
- Wikipedia
- Vaborbactam
- PDB Entries
- 4xux / 4xuz / 6td0 / 6v7h / 6v7i / 7auh / 7ly1 / 7tc1 / 8btw / 8bv4 … show 2 more
- FDA label
- Download (191 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Acute Tubulo-Interstitial Nephritis / Bacteremia / Complicated Urinary Tract Infection / Hospital-Acquired Pneumonia / Infection Abdominal / Ventilator Associated Bacterial Pneumonia (VABP) 1 somestatus stop reason just information to hide 3 Completed Treatment Acute Tubulo-Interstitial Nephritis / Complicated Urinary Tract Infection 1 somestatus stop reason just information to hide 3 Withdrawn Treatment Hospital-Acquired Pneumonia / Ventilator Associated Bacterial Pneumonia (VABP) 1 somestatus stop reason just information to hide 1 Completed Other Healthy Volunteers (HV) 1 somestatus stop reason just information to hide 1 Completed Treatment Bacterial Infections / Healthy Volunteers (HV) 3 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Intravenous - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US9694025 No 2017-07-04 2031-08-08 US US8680136 No 2014-03-25 2031-08-17 US US10183034 No 2019-01-22 2031-08-08 US US10172874 No 2019-01-08 2031-08-08 US US10561675 No 2020-02-18 2031-08-08 US US11007206 No 2021-05-18 2031-08-08 US US11376237 No 2019-04-06 2039-04-06 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.155 mg/mL ALOGPS logP 1.02 ALOGPS logP 1.86 Chemaxon logS -3.3 ALOGPS pKa (Strongest Acidic) 3.75 Chemaxon pKa (Strongest Basic) -2.6 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 95.86 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 67.14 m3·mol-1 Chemaxon Polarizability 29.67 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Enterobacter cloacae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.
- Specific Function
- beta-lactamase activity
- Gene Name
- ampC
- Uniprot ID
- P05364
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 41301.33 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein
- Organism
- Staphylococcus aureus
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- blaZ
- Uniprot ID
- P00807
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 31348.98 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
- Kind
- Protein
- Organism
- Klebsiella pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Hydrolyzes carbapenems, penicillins, cephalosporins and monobactams with varying efficiency.
- Specific Function
- beta-lactamase activity
- Gene Name
- bla
- Uniprot ID
- Q9F663
- Uniprot Name
- Carbapenem-hydrolyzing beta-lactamase KPC
- Molecular Weight
- 31114.99 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Mushtaq S, Vickers A, Doumith M, Ellington MJ, Woodford N, Livermore DM: Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2021 Jan 1;76(1):160-170. doi: 10.1093/jac/dkaa391. [Article]
- Kind
- Protein
- Organism
- Klebsiella pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- KPC-2
- Uniprot ID
- Q93LQ9
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 31114.99 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein group
- Organism
- Escherichia coli
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
Components:
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- blaSHV
- Uniprot ID
- A0A068JFB7
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 14354.285 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein
- Organism
- Klebsiella pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Broad-spectrum beta-lactamase which confers resistance to penicillins, as well as first- and third-generation cephalosporins (PubMed:10639363, PubMed:18955486, PubMed:19351161, PubMed:22908166, PubMed:23145056, PubMed:23252553). Has nitrocefin-hydrolyzing activity (PubMed:10231522, PubMed:19351161, PubMed:23252553). Inactive against the cephalosporins, cefotaxime and cefoxitin, and the carbapenem, meropenem (PubMed:10639363, PubMed:19351161).
- Specific Function
- beta-lactamase activity
- Gene Name
- bla
- Uniprot ID
- P0AD64
- Uniprot Name
- Beta-lactamase SHV-1
- Molecular Weight
- 31223.635 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- TEM-type are the most prevalent beta-lactamases in enterobacteria; they hydrolyze the beta-lactam bond in susceptible beta-lactam antibiotics, thus conferring resistance to penicillins and cephalosporins. TEM-3 and TEM-4 are capable of hydrolyzing cefotaxime and ceftazidime. TEM-5 is capable of hydrolyzing ceftazidime. TEM-6 is capable of hydrolyzing ceftazidime and aztreonam. TEM-8/CAZ-2, TEM-16/CAZ-7 and TEM-24/CAZ-6 are markedly active against ceftazidime. IRT-4 shows resistance to beta-lactamase inhibitors.
- Specific Function
- beta-lactamase activity
- Gene Name
- bla
- Uniprot ID
- P62593
- Uniprot Name
- Beta-lactamase TEM
- Molecular Weight
- 31514.865 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein
- Organism
- Klebsiella pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- MIR-1
- Uniprot ID
- Q9X757
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 41171.28 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
- Kind
- Protein
- Organism
- Klebsiella pneumoniae
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Not Available
- Specific Function
- beta-lactamase activity
- Gene Name
- fox-7
- Uniprot ID
- Q53IN1
- Uniprot Name
- Beta-lactamase
- Molecular Weight
- 41063.395 Da
References
- Lomovskaya O, Sun D, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley MN: Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: AAC.01443-17. doi: 10.1128/AAC.01443-17. Print 2017 Nov. [Article]
Drug created at October 20, 2016 21:22 / Updated at August 26, 2024 19:23